Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Curanex Pharmaceuticals Inc (CURX)

Curanex Pharmaceuticals Inc (CURX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,053
  • Shares Outstanding, K 28,341
  • Annual Sales, $ 0 K
  • Annual Income, $ -360 K
  • EBIT $ -1 M
  • EBITDA $ -1 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.05
  • Most Recent Earnings $-0.04 on 11/14/25
  • Next Earnings Date 07/17/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2713 +40.07%
on 02/12/26
0.6666 -42.99%
on 02/26/26
+0.0800 (+26.67%)
since 02/09/26
3-Month
0.2620 +45.04%
on 02/06/26
0.6666 -42.99%
on 02/26/26
-0.0968 (-20.30%)
since 12/09/25

Most Recent Stories

More News
Curanex Forms World Class Scientific Advisory Board

Board Includes Former Fortune 100 Pharma Executive and Leading US Medical Research Academic Jericho, New York, March 05, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex”...

CURX : 0.3800 (-2.56%)
Curanex Provides Operational Update on Key Regulatory Milestones

Company Completes GMP Pilot for Phyto-N, Targets Ulcerative Colitis IND Submission Q4 2026 Jericho, New York, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex”...

CURX : 0.3800 (-2.56%)
Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement

Jericho, New York, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental-stage pharmaceutical company focused on discovering...

CURX : 0.3800 (-2.56%)
Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters

Jericho, New York, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental stage pharmaceutical company focused on discovering...

CURX : 0.3800 (-2.56%)
Curanex Pharmaceuticals Inc. Announces Closing of its Initial Public Offering

Jericho, New York, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) ("Curanex" or the "Company"), a developmental stage pharmaceutical company focused on discovering and...

CURX : 0.3800 (-2.56%)
Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering

Jericho, New York, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) ("Curanex" or the "Company"), a developmental stage pharmaceutical company focused on discovering and...

CURX : 0.3800 (-2.56%)

Business Summary

Curanex Pharmaceuticals Inc. is a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases. Its lead candidate includes Phyto-N. Curanex Pharmaceuticals Inc. is headquartered in Jericho, New York.

See More

Key Turning Points

3rd Resistance Point 0.4267
2nd Resistance Point 0.4133
1st Resistance Point 0.3967
Last Price 0.3800
1st Support Level 0.3667
2nd Support Level 0.3533
3rd Support Level 0.3367

See More

52-Week High 9.1796
Fibonacci 61.8% 5.7731
Fibonacci 50% 4.7208
Fibonacci 38.2% 3.6685
Last Price 0.3800
52-Week Low 0.2620

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar